Paediatric patients with inflammatory bowel disease who received infliximab experienced improved growth and bone health

Acta Paediatrica, International Journal of Paediatrics

Volumn 103, Issue 2, 2014, Pages

  Pichler, Judith ^a   Hanslik, Andreas ^a   Huber, Wolf Dietrich ^a   Aufricht, Christoph ^a   Bidmon Fliegenschnee, Bettina ^a  

^a UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

Author keywords

Bone health; Bone mineral density; Children; Inflammatory bowel disease; Infliximab

Indexed keywords

INFLIXIMAB;

ADOLESCENT; ANTHROPOMETRY; ARTICLE; BODY MASS; BONE DENSITY; BONE MASS; CATCH UP GROWTH; CHILD; CHILD GROWTH; CHILDHOOD DISEASE; CLINICAL ARTICLE; FEMALE; GROWTH RETARDATION; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; MALE; NUTRITIONAL STATUS; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

BONE HEALTH; BONE MINERAL DENSITY; CHILDREN; INFLAMMATORY BOWEL DISEASE; INFLIXIMAB;

ADOLESCENT; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BONE AND BONES; BONE DENSITY; CHILD; CHILD, PRESCHOOL; FEMALE; GROWTH; HUMANS; INFLAMMATORY BOWEL DISEASES; INFUSIONS, INTRAVENOUS; MALE; RETROSPECTIVE STUDIES; WEIGHT GAIN;

EID: 84892613276     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/apa.12448     Document Type: Article

References (30)

1. Sylvester FA, Wyzga N, Hyams JS, Davis PM, Lerer T, Vance K, et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 42-50.
2. Gerasimidis K, McGrogan P, Edwards CA,. The aetiology and impact of malnutrition in paediatric inflammatory bowel disease. J Hum Nutr Diet 2011; 24: 313-26.
3. Walters TD, Griffiths AM,. Mechanisms of growth impairment in pediatric Crohn's disease. Nat Rev Gastroenterol Hepatol 2009; 6: 513-23.
4. Veerappan SG, O'Morain CA, Daly JS, Ryan BM,. Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 1261-72.
5. Malik S, Wong SC, Bishop J, Hassan K, McGrogan P, Ahmed SF, et al. Improvement in growth of children with Crohn disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr 2011; 52: 31-7.
6. Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, Otley AR, et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. Clin Gastroenterol Hepatol 2008; 6: 1378-84.
7. Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol 2006; 40: 55-63.
8. Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004; 36: 342-7.
9. Walters TD, Gilman AR, Griffiths AM,. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007; 13: 424-30.
10. Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS,. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease. J Gastroenterol Hepatol 2010; 25: 810-6.
11. Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2011; 106: 214-23.
12. Miheller P, Muzes G, Zagoni T, Toth M, Racz K, Tulassay Z,. Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease. Dig Dis 2006; 24: 201-6.
13. Mauro M, Radovic V, Armstrong D,. Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients. Can J Gastroenterol 2007; 21: 637-42.
14. IBD Working Group of the European Society for Paediatric Gastroenterology. Hepatology and nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr 2005; 41: 1-7.
15. Lennard-Jones JE,. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 2-6. discussion 9-16.
16. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011; 17: 1314-21.
17. Hyams J, Markowitz J, Otley A, Rosh J, Mack D, Bousvaros A, et al. Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005; 41: 416-21.
18. Prader A, Largo RH, Molinari L, Issler C,. Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development. Helv Paediatr Acta 1989; 52 (Suppl.): 1-125.
19. Carter DR, Bouxsein ML, Marcus R,. New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992; 7: 137-45.
20. Crabtree NJ, Kibirige MS, Fordham JN, Banks LM, Muntoni F, Chinn D, et al. The relationship between lean body mass and bone mineral content in paediatric health and disease. Bone 2004; 35: 965-72.
21. Hogler W, Briody JN, Woodhead HJ, Chan A, Cowell CT,. Importance of lean mass in the interpretation of total body densitometry in children and adolescents. J Pediatr 2003; 143: 81-8.
22. Pappa HM, Grand RJ, Saslowsky TM, Zholudev A, Horr B, Shih MC, et al. Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm Bowel Dis 2006; 12: 1162-74.
23. Griffiths AM, Hyams JS, Crandall W,. Height of children with active Crohn's disease improves during treatment with infliximab. Gastroenterology 2006; 130 (Suppl. 2): A59.
24. Vespasiani Gentilucci U, Caviglia R, Picardi A, Carotti S, Ribolsi M, Galati G, et al. Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. Aliment Pharmacol Ther 2005; 21: 1063-71.
25. Crombé V, Salleron J, Savoye G, Dupas JL, Vernier-Massouille G, Lerebours E, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis 2011; 17: 2144-52.
26. Assa A, Hartman C, Weiss B, Broide E, Rosenbach Y, Zevit N, et al. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease. J Crohns Colitis 2013; 7: 369-76.
27. Bernstein M, Irwin S, Greenberg GR,. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol 2005; 100: 2031-5.
28. Paganelli M, Albanese C, Borrelli O, Civitelli F, Canitano N, Viola F, et al. Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 416-23.
29. Leslie WD, Miller N, Rogala L, Bernstein CN,. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol 2008; 103: 1451-9.
30. Pappa H, Thayu M, Sylvester F, Leonard M, Zemel B, Gordon C,. Skeletal health of children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 53: 11-25.